MAXCYTE, INC. (MXCT)
Data as of , from SEC Form 4 filings.
See up to 3 months of MXCT. The 7-day demo opens the 1M and 3M ranges and puts MXCT on your watchlist.
Start 7-day demoData as of , from SEC Form 4 filings.
See up to 3 months of MXCT. The 7-day demo opens the 1M and 3M ranges and puts MXCT on your watchlist.
Start 7-day demo
Douglas J. Swirsky - OfficerDouglas J. Swirsky - Officer
Maher Masoud - Officer
Stanley C. Erck
Richard DouglasMaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
No Form 4 activity for MXCT in the last 90 days.
32 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| John Joseph Johnston | Grant or award | Common Stock | 30,421 footnote F1,F2 | $0.00 | - | |
| John Joseph Johnston | Grant or award | Stock Option (right to buy) | 49,579 | $0.00 | - | |
| ||||||
| Rekha Hemrajani | Grant or award | Common Stock | 30,421 footnote F1,F2 | $0.00 | - | |
| Rekha Hemrajani | Grant or award | Stock Option (right to buy) | 49,579 | $0.00 | - | |
| ||||||
| Stanley C. Erck | Grant or award | Common Stock | 30,421 footnote F1,F2 | $0.00 | - | |
| Stanley C. Erck | Grant or award | Stock Option (right to buy) | 49,579 | $0.00 | - | |
| ||||||
| Richard Douglas | Grant or award | Stock Option (right to buy) | 49,579 | $0.00 | - | |
| Richard Douglas | Grant or award | Common Stock | 30,421 footnote F1,F2 | $0.00 | - | |
| ||||||
| Cynthia Collins | Grant or award | Common Stock | 30,421 footnote F1,F2 | $0.00 | - | |
| Cynthia Collins | Grant or award | Stock Option (right to buy) | 49,579 | $0.00 | - | |
| ||||||
| William W. Brooke | Grant or award | Common Stock | 30,421 footnote F1,F2 | $0.00 | - | |
| William W. Brooke | Grant or award | Stock Option (right to buy) | 49,579 | $0.00 | - | |
| ||||||
| Patrick J. Balthrop | Grant or award | Stock Option (right to buy) | 49,579 | $0.00 | - | |
| Patrick J. Balthrop | Grant or award | Common Stock | 30,421 footnote F1,F2 | $0.00 | - | |
| ||||||
| Yasir B. Al-Wakeel | Grant or award | Stock Option (right to buy) | 49,579 | $0.00 | - | |
| Yasir B. Al-Wakeel | Grant or award | Common Stock | 30,421 footnote F1,F2 | $0.00 | - | |
| ||||||
| Parmeet Ahuja - Officer | Grant or award | Common Stock | 187,500 footnote F1 | $0.00 | - | |
| ||||||
| Parmeet Ahuja - Officer | Grant or award | Employee Stock Option (right to buy) | 375,000 | $0.00 | - | |
| Maher Masoud - Officer | Grant or award | Common Stock | 300,000 footnote F1 | $0.00 | - | |
| Maher Masoud - Officer | Grant or award | Employee Stock Option (right to buy) | 600,000 | $0.00 | - | |
| ||||||
| Douglas J. Swirsky - Officer | Open-market sale | Common Stock | 10,142 | $0.82 footnote F2 | $8K | |
| ||||||
| Douglas J. Swirsky - Officer | Open-market purchase | Common Stock | 50,000 | $1.29 | $65K | |
| Maher Masoud - Officer | Open-market purchase | Common Stock | 75,000 | $1.37 | $103K | |
| Stanley C. Erck | Open-market purchase | Common Stock | 100,000 | $1.37 | $137K | |
| Richard Douglas | Open-market purchase | Common Stock | 80,000 | $1.39 | $111K | |
| William W. Brooke | Open-market purchase | Common Stock | 50,000 | $1.29 | $65K | |
| Rekha Hemrajani | Open-market sale | Common Stock | 10,684 | $2.09 | $22K | |
| John Joseph Johnston | Grant or award | Common Stock | 29,210 | $0.00 | - | |
| John Joseph Johnston | Grant or award | Stock Option (right to buy) | 50,790 | $0.00 | - | |
| Rekha Hemrajani | Grant or award | Common Stock | 29,210 | $0.00 | - | |
| Rekha Hemrajani | Grant or award | Stock Option (right to buy) | 50,790 | $0.00 | - | |
| Stanley C. Erck | Grant or award | Common Stock | 29,210 | $0.00 | - | |
| Stanley C. Erck | Grant or award | Stock Option (right to buy) | 50,790 | $0.00 | - | |
| Cynthia Collins | Grant or award | Common Stock | 29,210 | $0.00 | - | |
| Cynthia Collins | Grant or award | Stock Option (right to buy) | 50,790 | $0.00 | - | |
| William W. Brooke | Grant or award | Common Stock | 29,210 | $0.00 | - | |
| William W. Brooke | Grant or award | Stock Option (right to buy) | 50,790 | $0.00 | - | |
| Yasir B. Al-Wakeel | Grant or award | Common Stock | 29,210 | $0.00 | - | |
| Yasir B. Al-Wakeel | Grant or award | Stock Option (right to buy) | 50,790 | $0.00 | - | |
| Patrick J. Balthrop | Grant or award | Common Stock | 29,210 | $0.00 | - | |
| Patrick J. Balthrop | Grant or award | Stock Option (right to buy) | 50,790 | $0.00 | - | |
| Richard Douglas | Grant or award | Common Stock | 29,210 | $0.00 | - | |
| Richard Douglas | Grant or award | Stock Option (right to buy) | 50,790 | $0.00 | - | |
| John Joseph Johnston | Option exercise | Common Stock | 3,000 | $2.93 | $9K | |
| John Joseph Johnston | Open-market sale | Common Stock | 3,000 | $4.01 | $12K | |
| John Joseph Johnston | Option exercise | Stock Option (right to buy) | 3,000 | $0.00 | - | |
| John Joseph Johnston | Option exercise | Common Stock | 505 | $2.93 | $1K | |
| John Joseph Johnston | Open-market sale | Common Stock | 505 | $3.70 | $2K | |
| John Joseph Johnston | Option exercise | Common Stock | 891 | $2.93 | $3K | |
| John Joseph Johnston | Option exercise | Common Stock | 1,121 | $1.64 | $2K | |
| John Joseph Johnston | Option exercise | Common Stock | 483 | $2.93 | $1K | |
| John Joseph Johnston | Open-market sale | Common Stock | 2,495 | $3.79 | $9K | |
| John Joseph Johnston | Option exercise | Stock Option (right to buy) | 505 | $0.00 | - | |
| John Joseph Johnston | Option exercise | Stock Option (right to buy) | 891 | $0.00 | - | |
| John Joseph Johnston | Option exercise | Stock Option (right to buy) | 1,121 | $0.00 | - | |
| John Joseph Johnston | Option exercise | Stock Option (right to buy) | 483 | $0.00 | - | |
| Stanley C. Erck | Option exercise | Common Stock | 47,689 | $0.04 | $2K | |
| Stanley C. Erck | Open-market sale | Common Stock | 47,689 | $3.72 | $177K | |
| Stanley C. Erck | Option exercise | Employee Stock Option (right to buy) | 47,689 | $0.00 | - | |
| John Joseph Johnston | Option exercise | Common Stock | 3,000 | $2.93 | $9K | |
| John Joseph Johnston | Open-market sale | Common Stock | 3,000 | $3.72 | $11K | |
| John Joseph Johnston | Option exercise | Stock Option (right to buy) | 3,000 | $0.00 | - | |
MAXCYTE, INC. (MXCT) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-06-22. The full record for MXCT runs to 32 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
No insider purchases of MXCT were filed in the last 90 days. 5 purchases are on record for this company.
No insider sales of MXCT were filed in the last 90 days. 9 sales are on record for this company.
This page collects MXCT Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
